REGULATORY UPDATE: FDA Issues Draft Guidance on Responding to Form 483 Observations After Drug CGMP Inspections

The Food and Drug Administration released a draft guidance on March 7 that outlines expectations for how manufacturers should respond to Form 483 inspectional observations issued at the conclusion of a drug CGMP inspection. The draft guidance applies to domestic and foreign manufacturers of human and animal drugs, biologics and combination products regulated by the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research and the Center for Veterinary Medicine.

The draft guidance is intended to address issues with inadequate responses to FDA 483 observations including, “a lack or omission of relevant data, excessive amounts of data, and/or failure to address the root cause of observations in the FDA 483.” FDA noted that poor quality responses limit its ability to evaluate corrective actions and assess potential patient or product risk, and limit the agency’s ability to help firms achieve voluntary compliance. The document emphasizes the importance of structured, timely and evidence-based responses.

While submitting a response to Form 483 is voluntary, FDA recommends providing a single consolidated submission within 15 business days, supported by thorough root cause investigations, well-defined CAPA plans and sufficient documentation. The draft guidance also underscores the need for executive-level commitment, including senior leadership signoff, and the integration of patient and product-focused risk assessments to demonstrate meaningful CGMP compliance.

Interested parties may submit electronic or written comments through May 8. Instructions are available in the Federal Register notice.